171 related articles for article (PubMed ID: 36603851)
21. A novel necroptosis-associated miRNA signature predicting prognosis of endometrial cancer and correlated with immune infiltration.
Ye Z; Jiang Y; Wu J
Taiwan J Obstet Gynecol; 2023 Mar; 62(2):291-298. PubMed ID: 36965898
[TBL] [Abstract][Full Text] [Related]
22. Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma.
Zhang X; Guo G; Wang G; Zhao J; Wang B; Yu X; Ding Y
Mol Med Rep; 2015 Dec; 12(6):8021-31. PubMed ID: 26497752
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
25. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
[TBL] [Abstract][Full Text] [Related]
26. Identification of miRNA-Based Signature as a Novel Potential Prognostic Biomarker in Patients with Breast Cancer.
Tang J; Ma W; Zeng Q; Tan J; Cao K; Luo L
Dis Markers; 2019; 2019():3815952. PubMed ID: 31976020
[TBL] [Abstract][Full Text] [Related]
27. A 3-miRNA signature predicts survival of patients with hypopharyngeal squamous cell carcinoma after post-operative radiotherapy.
Xu X; Lu Z; Gross N; Li G; Zhang F; Lei D; Pan X
J Cell Mol Med; 2019 Dec; 23(12):8280-8291. PubMed ID: 31578816
[TBL] [Abstract][Full Text] [Related]
28. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer.
Wang X; Meng X; Li H; Liu W; Shen S; Gao Z
Clin Transl Oncol; 2014 Nov; 16(11):954-8. PubMed ID: 24696291
[TBL] [Abstract][Full Text] [Related]
30. The conglomeration of diagnostic, prognostic and therapeutic potential of serum miR-199a and its association with clinicopathological features in epithelial ovarian cancer.
Zuberi M; Khan I; Gandhi G; Ray PC; Saxena A
Tumour Biol; 2016 Aug; 37(8):11259-66. PubMed ID: 26951510
[TBL] [Abstract][Full Text] [Related]
31. A Pilot Study of Circulating MicroRNA-125b as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer.
Zhu T; Gao W; Chen X; Zhang Y; Wu M; Zhang P; Wang S
Int J Gynecol Cancer; 2017 Jan; 27(1):3-10. PubMed ID: 27636713
[TBL] [Abstract][Full Text] [Related]
32. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma.
Zhang X; Ma L; Zhai L; Chen D; Li Y; Shang Z; Zhang Z; Gao Y; Yang W; Li Y; Pan Y
Int J Med Sci; 2021; 18(4):984-999. PubMed ID: 33456356
[TBL] [Abstract][Full Text] [Related]
33. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.
Zheng H; Zhang L; Zhao Y; Yang D; Song F; Wen Y; Hao Q; Hu Z; Zhang W; Chen K
PLoS One; 2013; 8(11):e77853. PubMed ID: 24223734
[TBL] [Abstract][Full Text] [Related]
34. Deregulation of Selected MicroRNAs in Sinonasal Squamous Cell Carcinoma: Searching for Potential Prognostic Biomarkers.
Kovaříková J; Baranová I; Laco J; Rozkošová K; Vošmíková H; Vošmík M; Dundr P; Němejcová K; Michálek J; Palička V; Chmelařová M
Folia Biol (Praha); 2019; 65(3):142-151. PubMed ID: 31638561
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
36. HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance.
Iramaneerat K; Rattanatunyong P; Khemapech N; Triratanachat S; Mutirangura A
Int J Gynecol Cancer; 2011 Jan; 21(1):51-7. PubMed ID: 21330831
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma.
Wu C; Wang C; Guan X; Liu Y; Li D; Zhou X; Zhang Y; Chen X; Wang J; Zen K; Zhang CY; Zhang C
PLoS One; 2014; 9(3):e92292. PubMed ID: 24651474
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
